- Home
- EARN vs CLLS Comparison
EARN vs CLLS Comparison
Compare EARN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- CLLS
- Stock Information
- Founded
- EARN 2012
- CLLS 1999
- Country
- EARN United States
- CLLS France
- Employees
- EARN N/A
- CLLS 216
- Industry
- EARN Real Estate Investment Trusts
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- EARN Real Estate
- CLLS Health Care
- Exchange
- EARN Nasdaq
- CLLS Nasdaq
- Market Cap
- EARN 187.6M
- CLLS 148.1M
- IPO Year
- EARN 2013
- CLLS 2007
- Fundamental
- Price
- EARN $6.62
- CLLS $1.48
- Analyst Decision
- EARN Hold
- CLLS Buy
- Analyst Count
- EARN 1
- CLLS 3
- Target Price
- EARN N/A
- CLLS $7.00
- AVG Volume (30 Days)
- EARN 506.5K
- CLLS 235.1K
- Earning Date
- EARN 03-05-2025
- CLLS 11-04-2024
- Dividend Yield
- EARN 14.50%
- CLLS N/A
- EPS Growth
- EARN 277.67
- CLLS N/A
- EPS
- EARN 1.02
- CLLS N/A
- Revenue
- EARN N/A
- CLLS $36,042,000.00
- Revenue This Year
- EARN N/A
- CLLS $387.77
- Revenue Next Year
- EARN $89.08
- CLLS $11.14
- P/E Ratio
- EARN $6.47
- CLLS N/A
- Revenue Growth
- EARN N/A
- CLLS 46.96
- 52 Week Low
- EARN $5.54
- CLLS $1.41
- 52 Week High
- EARN $7.26
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- EARN 50.97
- CLLS 38.66
- Support Level
- EARN $6.30
- CLLS $1.65
- Resistance Level
- EARN $6.61
- CLLS $2.23
- Average True Range (ATR)
- EARN 0.13
- CLLS 0.18
- MACD
- EARN -0.00
- CLLS -0.03
- Stochastic Oscillator
- EARN 57.14
- CLLS 8.54
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.